Limbic Stem Cells & Exosomes
Overview
At the heart of our regenerative ophthalmology solutions lies Limbic Stem Cells (LSCs) and Exosome Technology, developed through a groundbreaking collaboration. This innovative technology combines the regenerative power of LSCs and exosomes to deliver cutting-edge therapies for some of the most challenging eye conditions.
A Strategic Partnership
Our exclusive partnership with 3D Biotech ensures YD Biopharma has sole global rights to market and distribute these advanced solutions. While 3D Biotech specializes in the development and production of the patented technology, YD Biopharma takes the lead in bringing these transformative therapies to patients worldwide.
Exclusive Distribution Rights
YD Biopharma holds the sole marketing and distribution rights for 3D Biotech’s innovations, ensuring unique access to cutting-edge therapies.
Superior Production Technology
The patented technology achieves a 20-fold increase in cell growth within 5 days, significantly reducing production time and ensuring treatment availability.
Proven Safety and Compatibility
LSCs minimize immune rejection risks, ensuring safer and more effective treatments for patients.
Scalable and Reliable Supply
3D Biotech’s advanced manufacturing capabilities guarantee a consistent, high-quality supply chain, enabling YD Biopharma to meet global demand with confidence.
Dry Eye Syndrome
Exosome-based eye drops work at a cellular level to restore the natural tear film balance and repair damaged ocular tissues. The anti-inflammatory properties of exosomes reduce irritation and prevent further damage, offering long-term relief and improved ocular health.
Corneal Injuries
Utilizing the regenerative power of corneal mesenchymal stem cells and their exosomes, our technology accelerates the healing process by promoting tissue repair and reducing scar formation. This approach minimizes recovery time and improves overall treatment outcomes, restoring vision more effectively.
Glaucoma
Our exosome-based therapies target neuroprotection, helping preserve the health of the optic nerve while also addressing IOP. This dual-action approach offers a more comprehensive solution to managing glaucoma, potentially halting disease progression and preserving vision.
Therapeutic Contact Lenses
Our therapeutic contact lenses are infused with exosome-based solutions that continuously deliver regenerative and anti-inflammatory benefits. This innovation not only enhances comfort for contact lens wearers but also actively supports corneal healing and hydration, making them an ideal solution for managing dry eye syndrome and minor corneal injuries.
Exosome Eye Drops
Designed to treat dry eye syndrome and glaucoma with precision and efficacy.
Therapeutic Contact Lens Kits
Pushing boundaries to create groundbreaking medical technologies.
Exosome Isobuffer Solution
Supporting corneal repair and regeneration.
Product Line
Future Vision
With exclusive access to 3D Biotech’s advanced technology, YD Biopharma is committed to expanding the boundaries of regenerative vision care. Our goal is to make these innovative treatments accessible to patients worldwide, improving quality of life and redefining the standards of ophthalmology.
Experience the Exclusive Advantage
Partner with YD Biopharma and gain access to industry-leading Corneal Mesenchymal Stem Cell & Exosome therapies, made possible by our exclusive collaboration with 3D Biotech. Together, we’re shaping the future of vision care.
